Thermo Fisher Scientific Inc. TMO NYSE

Thermo Fisher Scientific Inc. (TMO) has shown declining revenue growth over the past 3 years, expanding from $44.9B to $44.6B (average -0.2%/yr). Net income reached $6.7B, reflecting earnings decline at -0.6%/yr on average. The net profit margin is 15.1%, which is high. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 37.7% (moderate), with a -5.7pp trend over the period. With a $196B market cap and MOAT composite score of 61/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (15/100, Fail) — revenue or earnings are not growing
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 41-year history, the company was profitable in 38 of 41 years — an excellent long-term track record
• INCOME (70/100, Pass) — proves strong profitability and pricing power
• MOAT (61/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 63/100 with 3/7 criteria passed.